Bharadwaj Apoorva V, Mendiratta Vibhu, Rehan Harmeet Singh, Tripathi Smita
Department of Dermatology and STD, Lady Hardinge Medical College, New Delhi, India.
Department of Pharmacology, Lady Hardinge Medical College, New Delhi, India.
Int J Trichology. 2023 Mar-Apr;15(2):56-62. doi: 10.4103/ijt.ijt_72_22. Epub 2023 Jul 28.
Androgenetic alopecia (AGA) is the most common cause of hair loss in males which remains a therapeutic challenge.
To compare the efficacy of topical 5% minoxidil and 0.25% finasteride combination (MNF) over 5% minoxidil (MNX) or 0.25% finasteride (FNS) alone by assessing hair count, physician assessment score (PAS), and patient satisfaction score (PSS).
Pilot randomized open-label study where 60 male patients with AGA ≥ III grade were randomized into three treatment groups and evaluated over 24 weeks. Improvement in hair count was assessed manually using dermoscopy. Global photographs were used to assess PAS. Side effects were evaluated using relevant laboratory investigations.
At the 12 and 24 week, all three groups showed significant improvement in total hair density as compared to baseline ( < 0.001). None of the groups was superior to the other ( > 0.05) at the 12 week but at 24 week, MNF was comparatively superior ( < 0.02). At the 12 week and 24 week, all three groups showed significant improvement in terminal hair density as compared to baseline ( < 0.001). In the 12 week, MNF was comparatively superior ( = 0.028) and at the 24 week, MNF was comparatively superior ( < 0.02). PAS and PSS were significantly better with MNF and MNX compared to FNS ( < 0.004). Side effects such as scaling and itching were reported with MNF and MNX.
Topical minoxidil 5% and finasteride 0.25% had an overall better efficacy compared to monotherapy without significant side effects.
雄激素性脱发(AGA)是男性脱发最常见的原因,仍然是一个治疗挑战。
通过评估毛发计数、医生评估评分(PAS)和患者满意度评分(PSS),比较外用5%米诺地尔和0.25%非那雄胺联合用药(MNF)与单独使用5%米诺地尔(MNX)或0.25%非那雄胺(FNS)的疗效。
一项先导性随机开放标签研究,将60例≥Ⅲ级AGA男性患者随机分为三个治疗组,进行24周的评估。使用皮肤镜手动评估毛发计数的改善情况。使用整体照片评估PAS。通过相关实验室检查评估副作用。
在第12周和第24周时,与基线相比,所有三组的总毛发密度均有显著改善(P<0.001)。在第12周时,没有一组优于其他组(P>0.05),但在第24周时,MNF相对更优(P<0.02)。在第12周和第24周时,与基线相比,所有三组的终毛密度均有显著改善(P<0.001)。在第12周时,MNF相对更优(P=0.028),在第24周时,MNF相对更优(P<0.02)。与FNS相比,MNF和MNX的PAS和PSS明显更好(P<0.004)。MNF和MNX报告有脱屑和瘙痒等副作用。
与单一疗法相比,外用5%米诺地尔和0.25%非那雄胺总体疗效更好,且无明显副作用。